Details of the Drug

General Information of Drug (ID: DM8JXPZ)

Drug Name
Glibenclamide
Synonyms
Abbenclamide; Adiab; Azuglucon; Bastiverit; Benclamin; Betanase; Calabren; Cytagon; Daonil; Debtan; Diabeta; Diabiphage; Dibelet; Duraglucon; Euclamin; Euglucan; Euglucon; Euglykon; Gewaglucon; Gilemal; Glamide; Glibadone; Gliban; Gliben; Glibenbeta; Glibenclamida; Glibenclamidum; Glibenil; Glibens; Glibesyn; Glibet; Glibetic; Glibil; Gliboral; Glicem; Glidiabet; Glimel; Glimide; Glimidstata; Glisulin; Glitisol; Glubate; Gluben; Glucobene; Glucohexal; Glucolon; Glucomid; Glucoremed; Glucoven; Glyben; Glybenclamide; Glybenzcyclamide; Glyburide; Glycolande; Glycomin; Glynase; Hexaglucon; Humedia; Lederglib; Libanil; Lisaglucon; Maninil; Melix; Micronase; Miglucan; Nadib; Neogluconin; Normoglucon; Orabetic; Pira; Praeciglucon; PresTab; Prodiabet; Renabetic; Sugril; Suraben; Tiabet; Yuglucon; Euglucon N; Glibenclamid AL; Glibenclamid Basics; Glibenclamid Fabra; Glibenclamid Genericon; Glibenclamid Heumann; Glibenclamid Riker M; Glyburide [USAN]; Micronized glyburide; Betanese 5; Euglucon 5; G 0639; GBN 5; HB 419; HB 420; HB419; HB420; Norglicem 5; U 26452; UR 606; Apo-Glibenclamide; Daonil (TN); Dia-basan; Diabeta (TN); Euglucon (TN); Gen-Glybe; Gliben-Puren N; Glibenclamid Riker M.; Glibenclamid-Cophar; Glibenclamid-Ratiopharm; Glibenclamida [INN-Spanish]; Glibenclamidum [INN-Latin]; Gluco-Tablimen; Glyburide (USP); Glyburide (micronized); Glynase (TN); HB-419; HB-420; Hemi-Daonil; Med-Glionil; Micronase (TN); Novo-Glyburide; Semi-Euglucon; Semi-daonil; U-26452; Glibenclamide (JP15/INN); Semi-Daonil (TN); Semi-Gliben-Puren N; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)-ethyl]benzene-sulfonyl-N-cyclohexylurea; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [1]
Non-insulin dependent diabetes 5A11 Approved [2]
Stroke 8B20 Phase 3 [3]
Therapeutic Class
Hypoglycemic Agents
Affected Organisms
Humans and other mammals
ATC Code
A10BB01: Glibenclamide
A10BB: Sulfonylureas
A10B: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10: DRUGS USED IN DIABETES
A: ALIMENTARY TRACT AND METABOLISM
A10BB01: Glibenclamide
A10BB: Sulfonylureas
A10B: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10: DRUGS USED IN DIABETES
A: ALIMENTARY TRACT AND METABOLISM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 494
Logarithm of the Partition Coefficient (xlogp) 4.8
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 348 mcgh/L [4]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 211-315 mcg/L [4]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 0.9-1.0 h [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability
82% of drug becomes completely available to its intended biological destination(s) [6]
Clearance
The clearance of drug is 2.70-3.55 L/h [4]
Elimination
50% of drug is excreted in the urine and 50% in the feces [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 4.0 - 13.4 hours [4]
Metabolism
The drug is metabolized via the CYP3A4, followed by CYP2C9, CYP2C19, CYP3A7, and CYP3A5 [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.57836 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.021% [10]
Vd
The volume of distribution (Vd) of drug is 21.5-49.3 L [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.004 mg/mL [5]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Haemolysis Not Available G6PD OT300SMK [11]
Chemical Identifiers
Formula
C23H28ClN3O5S
IUPAC Name
5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide
Canonical SMILES
COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
InChI
InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)
InChIKey
ZNNLBTZKUZBEKO-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3488
ChEBI ID
CHEBI:5441
CAS Number
10238-21-8
UNII
SX6K58TVWC
DrugBank ID
DB01016
TTD ID
D05LYX
VARIDT ID
DR00094
INTEDE ID
DR0775
ACDINA ID
D00304
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ATP-binding cassette transporter C8 (ABCC8) TTP835K ABCC8_HUMAN Modulator [12]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [13]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [14]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [15]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [16]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [17]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [18]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [16]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [19]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [19]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [20]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Gene/Protein Processing [21]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Gene/Protein Processing [21]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Gene/Protein Processing [21]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Gene/Protein Processing [22]
ATP-sensitive inward rectifier potassium channel 8 (KCNJ8) OTZ8G8FE KCNJ8_HUMAN Gene/Protein Processing [23]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [24]
Calpain-2 catalytic subunit (CAPN2) OTIAPE5J CAN2_HUMAN Gene/Protein Processing [25]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [25]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [25]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U2OS CTRP1 7.582 9.6469 4.376 0.8855
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MCF-7 CTRP1 6.9701 9.681 4.0792 3.3823
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GaMG CTRP1 6.4876 8.7754 4.2129 3.3566
SF295 CTRP1 6.8075 8.2652 4.5757 0.656
LN-229 CTRP1 6.9394 10.177 3.845 5.131
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MFE-319 CTRP1 6.4627 8.3731 4.3738 2.2529
HEC-108 CTRP1 6.6074 7.9973 4.5936 0.7493
HEC-151 CTRP1 6.7022 8.7443 4.3386 2.0908
KLE CTRP1 6.8596 9.2049 4.2246 2.585
HEC-59 CTRP1 6.9666 8.3667 4.6014 0.4449
HEC-265 CTRP1 6.9787 8.1008 4.699 0.168
HEC-6 CTRP1 6.9872 8.2749 4.6419 0.306
JHUEM-2 CTRP1 7.1696 8.9878 4.4536 0.8881
HEC-251 CTRP1 7.3625 8.8616 4.5744 0.3275
Ishikawa (Heraklio) 02 ER- CTRP1 6.7104 7.6414 4.7609 0.1216
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SU-DHL-5 CTRP1 5.2223 6.2175 4.6094 3.4229
WSU-DLCL2 CTRP1 5.4784 6.8341 4.4919 3.6127
U-937 CTRP1 6.0033 9.6907 3.4751 10.5987
NU-DUL-1 CTRP1 6.2857 22.0659 -2.4451 34.3924
AMO1 CTRP1 6.3414 7.5684 4.6444 0.7646
RPMI-8226 CTRP1 6.4019 8.9672 4.0781 4.5737
LP-1 CTRP1 6.5219 8.1163 4.5091 1.2959
KMS-11 CTRP1 6.551 9.6406 3.8598 5.9218
SU-DHL-4 CTRP1 6.5601 7.9045 4.609 0.7211
SKM-1 CTRP1 6.5713 7.9823 4.584 0.8316
PL21 CTRP1 6.6811 8.4072 4.4661 1.3396
MC116 CTRP1 6.8281 7.6589 4.795 0.0499
NOMO-1 CTRP1 6.8406 8.1929 4.6155 0.4733
EJM CTRP1 6.8793 8.5874 4.4836 1.0193
BL-70 CTRP1 6.9658 7.864 4.7736 0.0548
THP-1 CTRP1 7.0196 8.8522 4.4419 1.0842
HT CTRP1 7.0377 8.1153 4.7146 0.1228
Ku812 CTRP1 7.0556 8.7154 4.5089 0.7413
P3HR-1 CTRP1 7.2034 8.7832 4.5425 0.5074
OCI-AML-3 CTRP1 7.2343 8.4362 4.6746 0.1451
KE-97 CTRP1 7.2904 8.6112 4.6349 0.2071
OCI-Ly10 CTRP1 7.313 14.6277 1.9977 16.6758
GDM-1 CTRP1 7.5456 9.3277 4.478 0.5278
MOLM-16 CTRP1 7.5645 9.0962 4.5662 0.2699
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
VMRC-RCW CTRP1 6.6895 8.5917 4.3954 1.7497
RCC10RGB CTRP1 7.4168 8.5955 4.6838 0.0939
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LS123 CTRP1 5.4913 10.1115 2.8833 17.0272
SNU-81 CTRP1 5.8791 7.7293 4.3296 3.8519
HT-55 CTRP1 6.1815 8.1426 4.3216 3.1888
HT-29 CTRP1 6.2353 9.9627 3.5046 9.6289
NCI-H508 CTRP1 6.273 11.5093 2.781 14.9516
COLO 678 CTRP1 6.3399 8.5578 4.2265 3.5683
HCT 8 CTRP1 6.4066 7.8041 4.5809 1.0311
DLD-1 CTRP1 6.4878 7.7883 4.6227 0.7244
SNU-1040 CTRP1 6.5028 8.2047 4.4642 1.5947
SW620 CTRP1 6.553 8.4814 4.374 2.0983
LS513 CTRP1 6.5572 8.0527 4.5504 1.0203
MDST8 CTRP1 6.6064 8.2185 4.5071 1.2
HCT 116 CTRP1 6.6103 8.2048 4.5143 1.1551
SW480 CTRP1 6.7552 10.7112 3.4903 8.2617
SNU-C4 CTRP1 6.7964 7.8996 4.703 0.2218
COLO205 CTRP1 6.8704 7.8623 4.7419 0.1155
SW48 CTRP1 6.8873 9.0383 4.3075 2.0073
SW948 CTRP1 6.9035 8.5583 4.505 0.8912
LS411N CTRP1 7 8.1793 4.6797 0.2032
COLO 320 CTRP1 7.0077 9.9022 4.0036 3.8411
CW-2 CTRP1 7.071 9.2561 4.3059 1.7625
SK-CO-1 CTRP1 7.0829 8.8268 4.4784 0.8521
CL-40 CTRP1 7.0899 8.4601 4.6147 0.3366
GP2d CTRP1 7.1226 8.8111 4.5005 0.724
KM12 CTRP1 7.2122 9.1297 4.4178 1.0143
SNU-61 CTRP1 7.2869 8.9467 4.5157 0.5508
RCM-1 [Human ESC] CTRP1 7.3576 8.7797 4.601 0.2615
CL-34 CTRP1 7.3808 8.7326 4.6254 0.1995
HT115 CTRP1 7.5546 8.9565 4.6103 0.1806
LS180 CTRP1 7.6101 9.1477 4.5647 0.2576
SW403 CTRP1 7.7387 9.1735 4.6009 0.1528
SNU-175 CTRP1 7.7682 9.2962 4.5698 0.1998
SNU-C2A CTRP1 7.7935 9.8821 4.3736 0.7434
C2BBe1 CTRP1 7.8284 9.5638 4.4997 0.3335
LoVo CTRP1 7.8954 9.8024 4.4409 0.4632
SNU-C5 CTRP1 8.0314 9.8129 4.4866 0.2925
RKO CTRP1 8.1193 9.9577 4.4682 0.3043
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-6 CTRP1 6.4764 7.5212 4.7174 0.3362
Hep-G2 CTRP1 6.8241 9.0068 4.2897 2.2156
SNU-398 CTRP1 7.5739 9.2983 4.4991 0.4459
SNU-449 CTRP1 7.8478 9.5565 4.5092 0.3035
Cancer Drug Sensitivity Data Curated from 91 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H82 CTRP1 5.2251 6.8007 4.3223 5.9811
NCI-H1105 CTRP1 5.804 11.6497 2.362 19.3799
NCI-H1694 CTRP1 5.8697 8.2339 4.0856 5.9187
NCI-H1963 CTRP1 6.0201 8.2177 4.1906 4.6229
NCI-H1836 CTRP1 6.1186 8.0583 4.3232 3.3176
BEN CTRP1 6.1489 7.4429 4.6062 1.2272
NCI-H1930 CTRP1 6.2268 14.0619 1.4898 22.7353
LXF 289 CTRP1 6.3277 9.0668 3.9877 5.4703
NCI-H1876 CTRP1 6.3681 8.8408 4.1154 4.3615
NCI-H841 CTRP1 6.3943 9.2092 3.9629 5.5005
HCC1359 CTRP1 6.4345 7.3785 4.7524 0.2448
Calu-6 CTRP1 6.4444 9.2091 3.9932 5.1364
SCLC-21H CTRP1 6.4844 7.9072 4.5752 0.9706
NCI-H460 CTRP1 6.4985 7.924 4.5748 0.9566
NCI-H2023 CTRP1 6.5372 10.1243 3.6267 7.7902
SHP-77 CTRP1 6.5761 7.9435 4.6009 0.7443
NCI-H1299 CTRP1 6.6001 9.2049 4.0857 4.0684
HCC1195 CTRP1 6.632 8.4733 4.4163 1.7038
HCC2108 CTRP1 6.6333 8.6969 4.3239 2.2993
NCI-H2141 CTRP1 6.6975 8.3192 4.5082 1.087
NCI-H2286 CTRP1 6.7327 9.4362 4.0575 3.9992
COR-L88 CTRP1 6.739 8.4374 4.4803 1.1896
NCI-H661 CTRP1 6.7674 9.134 4.2073 2.8608
Sq-1 CTRP1 6.7762 8.0389 4.6462 0.4035
VMRC-LCD CTRP1 6.7833 8.4843 4.4816 1.132
HCC4006 CTRP1 6.8109 8.5186 4.4804 1.1078
Lu-65 CTRP1 6.8198 8.7389 4.3972 1.5593
NCI-H1944 CTRP1 6.8463 9.3233 4.1675 2.9944
KNS-62 CTRP1 6.8637 8.752 4.4121 1.4175
HCC44 CTRP1 6.9129 8.9425 4.3586 1.6625
NCI-H2172 CTRP1 6.9222 9.9162 3.951 4.3884
CAL-12T CTRP1 6.9693 9.2192 4.2728 2.1027
NCI-H2073 CTRP1 6.9823 9.3009 4.2455 2.2546
SK-LU-1 CTRP1 7.0072 8.6638 4.5084 0.7834
EPLC-272H CTRP1 7.0127 8.9915 4.3846 1.3909
NCI-H596 CTRP1 7.0201 8.7159 4.4941 0.836
HCC1833 CTRP1 7.0228 9.5802 4.1491 2.8149
NCI-H2122 CTRP1 7.0295 8.4129 4.6088 0.3849
Lu-99 CTRP1 7.0313 8.1614 4.6968 0.157
NCI-H1793 CTRP1 7.0506 8.6655 4.5254 0.6763
DV-90 CTRP1 7.0521 11.2907 3.4059 8.1296
NCI-H2126 CTRP1 7.0606 8.1261 4.7189 0.1107
NCI-H1568 CTRP1 7.0665 9.4029 4.2442 2.138
NCI-H2009 CTRP1 7.085 8.5886 4.567 0.4935
NCI-H1355 CTRP1 7.1038 9.441 4.2465 2.0708
NCI-H2030 CTRP1 7.1043 11.6732 3.2611 9.056
HCC78 CTRP1 7.1098 10.9641 3.5897 6.6348
LCLC-103H CTRP1 7.1105 8.3723 4.6528 0.2272
NCI-H2029 CTRP1 7.1225 9.435 4.2578 1.977
HCC33 CTRP1 7.146 8.914 4.4716 0.8283
NCI-H1573 CTRP1 7.1781 8.8049 4.5249 0.5875
NCI-H1781 CTRP1 7.1882 8.6375 4.5887 0.3662
HCC827 CTRP1 7.2018 9.8736 4.1159 2.7425
Calu-3 CTRP1 7.2192 8.8864 4.5113 0.611
LC-1/sq-SF CTRP1 7.241 8.6195 4.6144 0.2725
COR-L23 CTRP1 7.2518 8.6538 4.6064 0.2886
NCI-H1975 CTRP1 7.2672 8.6869 4.6005 0.2977
NCI-H23 CTRP1 7.2734 9.342 4.3625 1.2219
HARA [Human squamous cell lung carcinoma] CTRP1 7.2783 8.8049 4.5632 0.3987
COR-L279 CTRP1 7.2933 8.707 4.603 0.2808
NCI-H810 CTRP1 7.3149 8.8905 4.5466 0.4314
NCI-H650 CTRP1 7.3194 8.8958 4.5464 0.4296
NCI-H522 CTRP1 7.3208 9.2427 4.4202 0.9072
NCI-H2081 CTRP1 7.3257 8.9064 4.545 0.4308
NCI-H1915 CTRP1 7.3347 9.0571 4.4943 0.5978
COR-L51 CTRP1 7.3366 8.8649 4.5637 0.3689
EBC-1 CTRP1 7.3421 9.1014 4.4811 0.6421
NCI-H1755 CTRP1 7.3539 9.1663 4.462 0.7075
NCI-H1435 CTRP1 7.3594 8.7803 4.6015 0.2597
NCI-H2405 CTRP1 7.3679 9.7146 4.2588 1.6594
RERF-LC-KJ CTRP1 7.3931 8.9241 4.5638 0.3432
ChaGo-K-1 CTRP1 7.4049 10.717 3.8629 4.0772
NCI-H1373 CTRP1 7.4771 9.353 4.4424 0.6973
DMS 273 CTRP1 7.5691 8.9575 4.615 0.1684
COLO 668 CTRP1 7.5802 9.4236 4.4568 0.5792
NCI-H727 CTRP1 7.5965 9.2968 4.5081 0.4085
NCI-H1048 CTRP1 7.6223 9.2704 4.5267 0.3458
HCC15 CTRP1 7.6246 11.619 3.5897 5.5321
HCC2935 CTRP1 7.6369 9.4653 4.4635 0.5248
NCI-H3255 CTRP1 7.6806 9.2707 4.5477 0.2724
NCI-H441 CTRP1 7.7027 9.6585 4.4193 0.6359
T3M-10 CTRP1 7.7202 9.4514 4.4994 0.3776
LCLC-97TM1 CTRP1 7.7284 9.7184 4.4077 0.6612
NCI-H358 CTRP1 7.7506 9.6758 4.4315 0.5666
NCI-H1666 CTRP1 7.7916 9.6186 4.4671 0.4359
NCI-H2342 CTRP1 7.8313 9.809 4.4145 0.5775
COLO 699 CTRP1 7.9129 9.7604 4.4621 0.3965
NCI-H1792 CTRP1 7.9222 9.4803 4.5611 0.1771
NCI-H1437 CTRP1 7.9985 9.9402 4.4306 0.4453
NCI-H2110 CTRP1 8.0267 10.2864 4.3177 0.797
A-549 CTRP1 8.265 10.0416 4.4908 0.217
⏷ Show the Full List of 91 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-450 CTRP1 7.2418 8.5778 4.6291 0.2365
KYSE-140 CTRP1 7.7583 9.8592 4.3681 0.7879
KYSE-410 CTRP1 8.0161 9.6758 4.5278 0.213
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OVKATE CTRP1 6.304 10.6833 3.2046 11.7577
HEY A8 CTRP1 6.3385 8.9159 4.0637 4.8385
Caov-3 CTRP1 6.5235 10.6539 3.3677 9.8448
JHOS-4 CTRP1 6.5829 8.442 4.4053 1.8464
OAW42 CTRP1 6.5936 7.9715 4.5976 0.7436
OV7 CTRP1 6.6159 9.2209 4.0875 4.0217
EFO-21 CTRP1 6.6314 8.7435 4.3033 2.4416
COV318 CTRP1 6.6476 7.6538 4.7344 0.2006
IGROV-1 CTRP1 6.6634 11.4332 3.0893 11.523
JHOC-5 CTRP1 6.7053 8.2179 4.5509 0.8608
OVMANA CTRP1 6.7394 8.2206 4.5643 0.7647
OVCAR-4 CTRP1 6.7935 12.6499 2.5937 14.5734
OVK18 CTRP1 7.1414 12.7732 2.7686 12.404
JHOM-1 CTRP1 7.1585 8.6915 4.5583 0.4798
RMG-I CTRP1 7.1734 9.7116 4.1691 2.4481
COV434 CTRP1 7.3004 9.8256 4.1833 2.1778
SNU-840 CTRP1 7.3854 12.2895 3.1494 9.1458
TYK-nu CTRP1 7.4781 9.3401 4.4474 0.6774
SK-OV-3 CTRP1 7.4927 9.2444 4.4877 0.5254
OVCAR-8 CTRP1 7.4978 9.1513 4.5227 0.4125
COV644 CTRP1 7.5322 9.133 4.5418 0.3433
EFO-27 CTRP1 7.7311 10.0114 4.3007 1.087
COV362 CTRP1 7.8137 9.4133 4.546 0.2337
A2780 CTRP1 7.8807 9.9844 4.3705 0.6991
OV-90 CTRP1 7.8943 9.2286 4.6351 0.081
RMUG-S CTRP1 8.6486 17.7453 1.3997 16.3337
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HPAC CTRP1 6.6037 8.1459 4.5346 1.0525
PaTu 8902 CTRP1 6.799 7.9358 4.6914 0.2516
QGP-1 CTRP1 6.842 8.3369 4.563 0.6825
SUIT-2 CTRP1 6.8722 8.2926 4.5915 0.5426
KP-3 CTRP1 6.9598 10.791 3.5794 7.0672
CFPAC-1 CTRP1 7.2304 10.2018 3.9921 3.5124
Capan-2 CTRP1 7.2851 9.6072 4.2639 1.731
Panc 03.27 CTRP1 7.5093 8.8806 4.6202 0.174
HuP-T4 CTRP1 7.5511 9.4589 4.4328 0.6837
Panc 10.05 CTRP1 7.5541 9.0762 4.5693 0.2663
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2052 CTRP1 7.2651 8.6806 4.6019 0.2948
MSTO-211H CTRP1 7.5945 9.3531 4.4874 0.4713
NCI-H28 CTRP1 7.7849 9.7166 4.4299 0.5528
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PaCa-3 CTRP1 6.2884 8.3689 4.2814 3.2618
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-MEL-28 CTRP1 6.4402 7.1432 4.835 0.0605
Hs 936.T CTRP1 6.5284 7.6756 4.6816 0.4341
G-361 CTRP1 6.8606 8.3888 4.5512 0.7185
SK-MEL-1 CTRP1 7.0578 8.3664 4.6358 0.2916
SK-MEL-5 CTRP1 7.1134 8.347 4.6626 0.2038
A-375 CTRP1 7.275 8.7952 4.5654 0.3938
COLO 741 CTRP1 7.5055 9.7896 4.2901 1.3464
Hs 852.T CTRP1 7.6314 9.3543 4.5007 0.4134
Hs 944.T CTRP1 7.7715 9.1547 4.6183 0.1201
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HT-1080 CTRP1 6.4497 9.4156 3.9016 5.8463
RKN CTRP1 6.5376 7.9043 4.5995 0.7887
G-401 CTRP1 7.0882 9.6137 4.1678 2.5867
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Fu97 CTRP1 6.7037 8.5655 4.4128 1.6231
SH-10-TC CTRP1 6.7281 7.9131 4.673 0.3411
AGS CTRP1 6.8359 8.4492 4.518 0.8935
MKN7 CTRP1 7.6471 9.1945 4.5619 0.2518
MKN74 CTRP1 7.7528 9.6787 4.4313 0.566
NUGC-4 CTRP1 7.923 9.6812 4.4932 0.3144
SNG-M CTRP1 7.4725 9.0573 4.5463 0.3566
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-2 CTRP1 6.8953 8.2192 4.6271 0.3991
SCC-9 CTRP1 7.725 9.757 4.3923 0.7191
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
5637 CTRP1 6.8257 8.7088 4.412 1.4658
UM-UC-3 CTRP1 7.0722 8.9443 4.4291 1.0946
RT-4 CTRP1 7.1636 8.9713 4.4574 0.8764
KMBC-2 CTRP1 7.1821 8.9418 4.476 0.7801
HT-1376 CTRP1 7.306 9.3451 4.3753 1.1272

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Glibenclamide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Glibenclamide due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [26]
Tromethamine DMOBLGK Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Glibenclamide caused by Tromethamine mediated altered urine pH. Acidosis [5C73] [27]
Arn-509 DMT81LZ Moderate Accelerated clearance of Glibenclamide due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [28]
Oxymetholone DMFXUT8 Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Oxymetholone. Aplastic anaemia [3A70] [29]
Clarithromycin DM4M1SG Moderate Increased plasma concentration of Glibenclamide and Clarithromycin due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [30]
Ag-221 DMS0ZBI Moderate Decreased clearance of Glibenclamide due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [31]
Alpelisib DMEXMYK Moderate Increased metabolism of Glibenclamide caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Fluoxymesterone DMUHCF1 Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Fluoxymesterone. Breast cancer [2C60-2C6Y] [29]
Fenofibric acid DMGO2MC Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [29]
Anisindione DM2C48U Moderate Increased plasma concentration of Glibenclamide and Anisindione due to competitive binding of plasma proteins. Coagulation defect [3B10] [33]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Glibenclamide caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [34]
MK-8228 DMOB58Q Moderate Decreased metabolism of Glibenclamide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [35]
Sertraline DM0FB1J Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Sertraline. Depression [6A70-6A7Z] [29]
Vilazodone DM4LECQ Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Vilazodone. Depression [6A70-6A7Z] [29]
Selegiline DM6034S Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Selegiline. Depression [6A70-6A7Z] [29]
Vortioxetine DM6F1PU Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Vortioxetine. Depression [6A70-6A7Z] [29]
Isocarboxazid DMAF1NB Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Isocarboxazid. Depression [6A70-6A7Z] [29]
SODIUM CITRATE DMHPD2Y Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Glibenclamide caused by SODIUM CITRATE mediated altered urine pH. Discovery agent [N.A.] [27]
Miconazole DMPMYE8 Major Decreased metabolism of Glibenclamide caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [29]
Sunitinib DMCBJSR Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [29]
Sulfinpyrazone DMEV954 Moderate Decreased renal excretion of Glibenclamide caused by Sulfinpyrazone. Gout [FA25] [28]
Rifampin DMA8J1G Moderate Increased metabolism of Glibenclamide caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [36]
Rifapentine DMCHV4I Moderate Increased metabolism of Glibenclamide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [37]
Fostemsavir DM50ILT Moderate Decreased clearance of Glibenclamide due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [38]
Etravirine DMGV8QU Moderate Decreased metabolism of Glibenclamide caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [39]
Bempedoic acid DM1CI9R Moderate Decreased clearance of Glibenclamide due to the transporter inhibition by Bempedoic acid. Hyper-lipoproteinaemia [5C80] [40]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Glibenclamide caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [41]
Gemfibrozil DMD8Q3J Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Gemfibrozil. Hyper-lipoproteinaemia [5C80] [29]
Fenofibrate DMFKXDY Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Fenofibrate. Hyper-lipoproteinaemia [5C80] [29]
Captopril DM458UM Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Captopril. Hypertension [BA00-BA04] [29]
Sodium acetate anhydrous DMH21E0 Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Glibenclamide caused by Sodium acetate anhydrous mediated altered urine pH. Hypo-osmolality/hyponatraemia [5C72] [27]
Probenecid DMMFWOJ Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Probenecid. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [29]
PF-06463922 DMKM7EW Moderate Increased metabolism of Glibenclamide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [31]
Hydroxychloroquine DMSIVND Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Hydroxychloroquine. Malaria [1F40-1F45] [29]
Sulphadoxine DMZI2UF Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Sulphadoxine. Malaria [1F40-1F45] [29]
Mecasermin DM1O3BY Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Mecasermin. Multiple structural anomalies syndrome [LD2F] [29]
Olaparib DM8QB1D Moderate Decreased clearance of Glibenclamide due to the transporter inhibition by Olaparib. Ovarian cancer [2C73] [31]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Glibenclamide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [42]
Safinamide DM0YWJC Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Safinamide. Parkinsonism [8A00] [29]
Rasagiline DM3WKQ4 Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Rasagiline. Parkinsonism [8A00] [29]
Abametapir DM2RX0I Moderate Decreased metabolism of Glibenclamide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [43]
Lefamulin DME6G97 Moderate Decreased metabolism of Glibenclamide caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [44]
Choline salicylate DM8P137 Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Choline salicylate. Postoperative inflammation [1A00-CA43] [29]
Enzalutamide DMGL19D Moderate Increased metabolism of Glibenclamide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [45]
Darolutamide DMV7YFT Moderate Decreased clearance of Glibenclamide due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [28]
Salsalate DM13P4C Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Salsalate. Rheumatoid arthritis [FA20] [29]
Leflunomide DMR8ONJ Moderate Decreased metabolism of Glibenclamide caused by Leflunomide mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [46]
Larotrectinib DM26CQR Moderate Decreased metabolism of Glibenclamide caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [31]
Ifosfamide DMCT3I8 Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [29]
Methyltestosterone DMWLFGO Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [29]
Eltrombopag DMOGFIX Moderate Decreased clearance of Glibenclamide due to the transporter inhibition by Eltrombopag. Thrombocytopenia [3B64] [47]
Pramlintide DM0EZ9Q Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Pramlintide. Type-1/2 diabete [5A10-5A11] [29]
Olsalazine DMZW9HA Moderate Increased risk of hypoglycemia by the combination of Glibenclamide and Olsalazine. Ulcerative colitis [DD71] [29]
⏷ Show the Full List of 53 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Calcium carbonate E00198 10112 Binding agent; Buffering agent; Diluent; Opacifying agent
D&C red no. 27 E00381 83511 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate E00671 Not Available Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
⏷ Show the Full List of 19 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Glyburide 6 mg tablet 6 mg Oral Tablet Oral
Glyburide 3 mg tablet 3 mg Oral Tablet Oral
Glyburide 2.5 mg tablet 2.5 mg Oral Tablet Oral
Glyburide 5 mg tablet 5 mg Oral Tablet Oral
Glyburide 1.5 mg tablet 1.5 mg Oral Tablet Oral
Glyburide 1.25 mg tablet 1.25 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2414).
2 Spectroscopic interactions of non-insulin-dependent diabetes mellitus with levocetirizine. Pak J Pharm Sci. 2021 Jul;34(4(Supplementary)):1639-1644.
3 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4 Pharmacokinetics and pharmacodynamics of glyburide in young and elderly patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother. 1996 May;30(5):472-5. doi: 10.1177/106002809603000507.
5 BDDCS applied to over 900 drugs
6 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
7 FDA Approved Drug Products: Glynase (Glyburide) Oral Tablets
8 Silberstein SD, McCrory DC: Butalbital in the treatment of headache: history, pharmacology, and efficacy. Headache. 2001 Nov-Dec;41(10):953-67.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102.
14 Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23.
15 Glyburide transport across the human placenta. Obstet Gynecol. 2015 Mar;125(3):583-8.
16 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17 Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos. 2010 May;31(4):228-42.
18 Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
19 Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 2014 Dec 15;92(4):690-700.
20 Chromatographic studies of changes in binding of sulfonylurea drugs to human serum albumin due to glycation and fatty acids. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Nov 15;878(30):3193-7. doi: 10.1016/j.jchromb.2010.09.033. Epub 2010 Oct 23.
21 Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
22 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
23 The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br J Pharmacol. 2010 Feb 1;159(3):650-8. doi: 10.1111/j.1476-5381.2009.00557.x. Epub 2009 Dec 24.
24 Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet. 2003;18(1):16-22.
25 A potential role of calpains in sulfonylureas (SUs) -mediated death of human pancreatic cancer cells (1.2B4). Toxicol In Vitro. 2021 Jun;73:105128. doi: 10.1016/j.tiv.2021.105128. Epub 2021 Feb 27.
26 Kivisto KT, Neuvonen PJ "Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide." Eur J Clin Pharmacol 42 (1992): 675-80. [PMID: 1623912]
27 Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6. [PMID: 1646724]
28 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
29 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
30 Bussing R, Gende A "Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction." Diabetes Care 25 (2002): 1659-61. [PMID: 12196446]
31 Cerner Multum, Inc. "Australian Product Information.".
32 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
33 Hansen JM, Christensen LK "Drug interactions with oral sulphonylurea hypoglycaemic drugs." Drugs 13 (1977): 24-34. [PMID: 401727]
34 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
35 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
36 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
37 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
38 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
39 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
40 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
41 Appel S, Rufenacht T, Kalafsky G, et al. "Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus." Am J Cardiol 76 (1995): a29-32. [PMID: 7604792]
42 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
43 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
44 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
45 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
46 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
47 Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]